摘要
目的系统评价中国莫西沙星治疗耐多药肺结核的疗效,为临床用药提供参考依据。方法通过搜索中国期刊全文数据库(CNKI)、中文科技期刊全文数据库(VIP)、万方数据库和中国生物医学文献数据库(CBM)中2000年1月到2017年12月所有莫西沙星治疗耐多药肺结核的随机对照试验(RCT),并采用Cochrane协作网提供的RevMan 5.3进行Meta分析。结果最终纳入36篇RCT,合计3025名研究对象。Meta分析结果显示,治疗组3个月末痰菌阴转率、疗程结束后的痰菌阴转率、疗程结束后的空洞闭合率、疗程结束后的病灶吸收率均高于对照组,差异均有统计学意义。莫西沙星组不良反应率低于对照组,差异有统计学意义。结论莫西沙星可以有效治疗耐多药肺结核,并且不良反应较少。
Objective To systematically evaluate the effectiveness and safety of moxifloxacinin in treating muti-drug resistant tuberculosis(MDR-TB),so as to provide theoretical basis for clinical treatment.Methods CNKI,CBM,Wanfang and VIP database were electronically searched to collect randomized controlled trials(RCTs)of moxifloxacin for MDR-TB from Jan 2000 to Dec 2017.RevMan 5.3 software of cochrane cooperation network was applied for statistical analysis.Results A total of 36 RCTs involving 3025 cases were included.The results of the Meta-analysis showed that as compared with the control group,moxioxacin could increase the sputum negative conversion rate after 3 months and at the end of the treatment period;moxifloxacin group was also superior to the control group on the cavity closure and focus absorption;the adverse reaction rate was lower in the moxifloxacin group than in the controls.All the differences were statistically significant.Conclusion Moxifloxacin is eective and safe in treatment of MDR-TB.
作者
武士青
方秦
李秀秀
田婷婷
吕美霞
Wu Shiqing;Fang Qin;Li Xiuxiu(Department of Epidemiology and Biostatistics;Department of Occupational and Environmental Health the Ministry of Education Key Laboratory of Environment and Health,School of Public Health,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)
出处
《华中科技大学学报(医学版)》
CAS
CSCD
北大核心
2018年第3期354-360,共7页
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
关键词
莫西沙星
耐多药肺结核
随机对照试验
META分析
moxifloxacin
multi drug resistant tuberculosis
randomized controlled trials
Meta analysis